Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

Novo Nordisk A/S’s blockbuster drug Wegovy was targeted for price cuts by the US government and suffered a setback in a new ...

The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...

The Centers for Medicare & Medicaid Services just announced 15 new drugs it wants to lower the cost for including popular, ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Biden administration says popular weight loss drugs have been added to Medicare’s list of medications that will be negotiated ...

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...

Wegovy (semaglutide) is a prescription drug used ... a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.

Wegovy comes as a liquid solution inside a prefilled ... Years of research and testing are needed to ensure that brand-name drugs are safe and effective. This testing can make the drugs expensive.